Developed by researchers at Israel’s Weizmann Institute and Sourasky Medical Center, the U.S. Food and Drug Administration fast-tracked the approval for their cancer treatment Yescarta, based on technology that uses the patient’s immune system to destroy cancer cells.
• List price in U.S. for the personally tailored drug is $373,000.
By Hezi Sternlicht & Israel Hayom Staff
Kite Pharma, founded by Israeli-American Professor Arie Belldegrun in 2009, has announced that the U.S. Food and Drug Administration has granted regular approval for its cancer treatment Yescarta.
California-based Gilead Sciences bought Kite Pharma for $12 billion in August this year.
Professor Arie Belldegrun – Photo: Kite Pharma
The product, which was approved on a fast-track process, is based on innovative technology that recruits the body’s immune system to identify and destroy cancer cells. Continue Reading »
Israeli New Shekel Exchange Rate